GeneOne Life Science Inc (011000)

Currency in KRW
865
+15(+1.76%)
Closed·
011000 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
800926
52 wk Range
6184,270
Key Statistics
Bid/Ask
862.00 / 865.00
Prev. Close
850
Open
848
Day's Range
800-926
52 wk Range
618-4,270
Volume
2.67M
Average Volume (3m)
3.74M
1-Year Change
-63.1236%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
011000 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

GeneOne Life Science Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
07/04/2026
EPS / Forecast
-196.00 / --
Revenue / Forecast
2.65B / --
EPS Revisions
Last 90 days

Compare 011000 to Peers and Sector

Metrics to compare
011000
Peers
Sector
Relationship
P/E Ratio
−1.5x−14.4x−0.5x
PEG Ratio
0.500.010.00
Price/Book
1.9x2.0x2.6x
Price / LTM Sales
3.3x4.7x3.2x
Upside (Analyst Target)
-40.0%50.8%
Fair Value Upside
Unlock15.7%7.7%Unlock

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA under phase 2 stage for the treatment of SARS-CoV-2; GLS-5100 under pre-clinical stage for prevention of herpes zoster; and GLS-5140 under pre-clinical stage for the treatment of SFTS prophylaxis. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C re-infection prophylaxis, as well as GLS-6100 that is in pre-clinical stage for hepatitis C prophylaxis. Further, the company’s discovery and optimization stage pipeline comprise GLS-7000 for the treatment of breast cancer; GLS-7100 for treating hemophilia A; GLS-8000 for the prevention of chronic hepatitis B; and GLS-8100 for treating rheumatoid arthritis. Additionally, it engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
3.33M3.67%2.83B
Other Institutional Investors
10.35M11.42%8.80B
Public Companies & Retail Investors
76.99M84.91%65.44B
Total
90.67M100.00%77.07B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard STAR Funds - Vanguard Total International Stock ETF1.16%1,052,627894,733
Vanguard Tax-Managed Funds - Vanguard FTSE Developed Markets ETF0.79%715,058607,799

People Also Watch

61,600
077970
-7.37%
48,050
007340
+12.27%
1,190,000
003240
-2.38%
150,000
456040
+6.01%
52,600
003920
-0.57%

FAQ

What Is the GeneOne Life Science (Seoul: 011000) Share Price Today?

The GeneOne Life Science stock price today is 865 KRW.

What Stock Exchange Does GeneOne Life Science (011000) Trade On?

GeneOne Life Science is listed and trades on the Seoul Stock Exchange.

What Is the Ticker (Stock Symbol) for GeneOne Life Science?

The stock symbol (also called a 'ticker') for GeneOne Life Science is "011000."

What Is the Current GeneOne Life Science Market Capitalisation?

As of today, GeneOne Life Science (Seoul: 011000) market cap is 77.07B KRW.

What Is GeneOne Life Science's (011000) Earnings Per Share (TTM)?

The GeneOne Life Science EPS is currently -629 (Trailing Twelve Months).

Is 011000 a Buy or Sell From a Technical Analyst Perspective?

Based on today's GeneOne Life Science moving averages and other technical indicators, the daily buy/sell signal for 011000 stock is Strong Sell.

How Many Times Has GeneOne Life Science Stock Split?

GeneOne Life Science has split 14 times. (See the 011000 stock split history page for full effective split date and price information.)

How Many Employees Does GeneOne Life Science Have?

GeneOne Life Science has 41 employees, based on their latest Companies House report.

What is the current trading status of GeneOne Life Science (Seoul: 011000)?

As of 30/04/2026, GeneOne Life Science (011000) is trading at a share price of 865 KRW, with a previous close of 850 KRW. The stock has fluctuated within a day range of 800 KRW to 926 KRW, while its 52-week range spans from 618 KRW to 4,270 KRW.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.